HALO Funding: How Much Did They Raise & Key Investors

How Much Did HALO Raise?
Funding & Key Investors

HALO, a specialized provider of advanced protein column solutions, has successfully secured a major strategic investment, bringing its total capital infusion to $350K. This latest financing round, which contributed $350K to the company's balance sheet, underscores the firm's critical role in the biopharmaceutical and environmental testing sectors. By leveraging this influx of liquidity, HALO is positioned to accelerate its operational footprint and solidify its market standing as a leader in high-performance chromatography materials.

The recent capital injection serves as a testament to the company's sustained growth trajectory and its ability to deliver high-value solutions for complex molecular separation challenges. As the industry shifts toward more rigorous purification standards, HALO remains at the forefront of innovation, ensuring that its proprietary technology meets the evolving demands of global research and manufacturing entities.

What is HALO?

HALO

Business Services

Research & Development

Manufacturing

HALO is a specialized manufacturer of high-efficiency protein column solutions, developed by Advanced Materials Technology. The company provides essential infrastructure for biopharma, environmental monitoring, and small molecule analysis. By utilizing advanced material science, HALO enables laboratories and industrial manufacturers to achieve superior resolution and throughput in their analytical processes. Its market position is defined by a commitment to precision, reliability, and the scalability of its chromatography products, which are integral to the development of modern therapeutics and environmental safety protocols.

How much funding has HALO raised?

HALO has raised a total of $350K across 1 funding round:

2020

Debt

$350K

Debt (2020): $350K with participation from PPP

Key Investors in HALO

PPP

Public-Private Partnership

What's next for HALO?

With the successful closure of this late-stage financing, HALO is expected to prioritize the expansion of its manufacturing capacity and the diversification of its product portfolio. The strategic allocation of these funds will likely focus on scaling production to meet the rising demand for high-purity protein separation tools in the biopharmaceutical sector. Furthermore, the company is well-positioned to explore new market segments, potentially enhancing its research and development capabilities to address emerging challenges in small molecule synthesis and environmental diagnostics. This capital deployment strategy is designed to drive long-term value creation and maintain the company's competitive edge in the specialized materials market.

See full HALO company page

See More Financial Insights